Genotypic resistance testing of HCV – is there a clinical need?
Persistent infections with the hepatitis C virus (HCV) pose a profound global public health burden. In the past 5 years treatment of chronic hepatitis C has dramatically changed. Novel direct-acting antivirals (DAAs) specifically inhibiting viral enzymes or factors that are essential for the viral r...
Main Authors: | Walker, Andreas, Kaiser, Rolf, Bartenschlager, Ralf, Timm, Jörg |
---|---|
Format: | Article |
Language: | English |
Published: |
German Medical Science GMS Publishing House
2016-08-01
|
Series: | GMS Infectious Diseases |
Subjects: | |
Online Access: | http://www.egms.de/static/en/journals/id/2016-4/id000023.shtml |
Similar Items
-
Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b
by: Mircea Manuc, et al.
Published: (2021-03-01) -
Efficacy and safety of direct-acting antiviral agent regimens in a real-world cohort of adult Chinese patients with chronic hepatitis C virus infection
by: Jinyuan Wei, et al.
Published: (2020-06-01) -
Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents
by: Elnaz Agi, et al.
Published: (2020-01-01) -
Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01) -
Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis
by: Tom Domovitz, et al.
Published: (2021-02-01)